A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

Exclusion Criteria10

• other malignancies previously or at the same time that are different from the primary site or histology of the tumor assessed in this study, except cervical carcinoma in situ, basal-cell carcinoma that has been fully treated, superficial bladder tumor (Ta, Tis, T1) or other malignancies that occurred before the enrollment and have been cured for more than 3 years;
• renal decompensation requires hemodialysis or peritoneal dialysis;
• arrhythmia need anti-arrhythmic treatment, symptomatic coronary artery disease or myocardial ischemia (myocardial infarction), nearly six months, or congestive heart failure than NYHA Ⅱ level; Hypertension (systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg) that has been treated with 2 or more antihypertensive treatments and still cannot be controlled;
• severe active clinical infection;
• patients with coagulation disorder or bleeding constitution;
• major surgery or severe trauma was performed within 4 weeks before enrollment;
• a history of allogeneic organ transplantation or bone marrow transplantation;
• drug abuse and medical, psychological or social conditions that may interfere with patients' participation in research or affect the evaluation of results;
• known or suspected allergy to the study drug;
• those who received treatment other than this study within 4 weeks prior to and during the study period.